MedTrace Logo

Twenty Years' Experience in Retroperitoneal Lymph Node Dissection for Testicular Cancer in a Tertiary Referral Center

NCT06806917 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 65

Last updated 2025-02-04

No results posted yet for this study

Summary

The aim of this study is to evaluate the oncologic and functional outcomes of RPLND as primary treatment (stage I and IIA-IIB with negative markers) or of residual masses after chemotherapy (PC-RPLND) in the treatment of patients with seminomatous and non-seminomatous.

In order to evaluate the role and the͛clinical impact of different surgical techniques of RPLND will be included patients treated with open, laparoscopic, and robot-assisted techniques

Conditions

  • Testicular Cancer

Sponsors & Collaborators

  • IRCCS Azienda Ospedaliero-Universitaria di Bologna

    lead OTHER

Principal Investigators

  • Eugenio Brunocilla, MD · IRCCS Azienda Ospedaliero-Universitaria di Bologna

Eligibility

Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-12-01
Primary Completion
2026-10-31
Completion
2031-10-31

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06806917 on ClinicalTrials.gov